Li and Liu organize water-soluble conjugated polymer (CP) protein sensors into three transduction classes: (1) cationic poly(thiophene) conformational changes producing colorimetric/fluorescent shifts (e.g., P1 wrapping a thrombin aptamer quadruplex, LOD 2Γ10β15 mol in 200 Β΅L); (2) super-quenching/dequenching of PPVs and PPEs via the Stern-Volmer amplified quenching mechanism (QTL and charge-neutral complex strategies, CNC assay LOD 300 nM); and (3) FRET-amplified assays using poly(fluorene-co-phenylene) donors with dye acceptors, including NP-amplified goat IgG detection at 1 ng/mL . The classification is logically clean and maps mechanisms to polymer backbones (PT, PPV, PPE, PFP) usefully for assay designers.
Bar lengths reflect molar-equivalent LODs converted from the review's reported values; the biochip value assumes the molecular count equals moles (1.5Γ10β· molecules β 2.5Γ10β»ΒΉβ· mol). Con A entry shows the linear quantification range, not an LOD .
Strengths: The review honestly acknowledges its central limitation β nonspecific CPβprotein interactions in biological media β and highlights how Heeger/Bazan's charge-neutral complex concept and the authors' surface-charge-switch aptamer assay (lysozyme detection in urine) directly mitigate it. Array-based pattern recognition (gold NP/PPE and oligofluorene/ssDNA-C* arrays discriminating 14β17 proteins at up to 97% accuracy) is presented as the field's most clinically promising direction. The inclusion of aggregation-induced FRET for naked-eye readouts extends the platform beyond instrument-dependent detection.
Caveats: As a narrative review, it is vulnerable to positive-result bias β nearly all cited systems show successful demonstrations with limited replication data, and LODs are reported under optimized purified-protein conditions rather than serum or plasma matrices. The review itself concedes most homogeneous assays fail in biological media, and it does not quantify how sensitivity degrades in such matrices. The mechanism attributions (electron transfer vs. aggregation for cyt c quenching) evolved between studies, showing that even the mechanistic picture was then unsettled β a healthy sign of conjecture but a warning against over-reading single-mechanism claims. Subsequent work, such as the plasmonic CPβsilver nanoprism nanoruler for label-free PSA/cancer-cell detection, confirmed the field's continued vitality but also its persistent LOD constraints (PSA LOD ~9.7 Β΅g/mL, far above clinical thresholds) . A companion mini-review reaches the same conclusion: solubility, specificity, and in vivo translation remain the field's unresolved challenges .
What would change this assessment: rigorous head-to-head validation of CP assays against ELISA in serum, batch-to-batch polymer characterization data, and standardized control panels (multiple nonspecific proteins at matched concentrations). None are supplied in the reviewed literature, so the field's claimed femtomolar-to-nanomolar sensitivities should be treated as optimized-case values, not clinical performance guarantees.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.